POLEN

A PREOPERATIVE “WINDOW-OPPORTUNITY”, MULTICENTER, PHARMACOKINETIC-PHARMACODYNAMIC STUDY TO EVALUATE THE INHIBITORY EFFECTS OF SINGLE AGENT AZD2281 (OLAPARIB), IN PATIENTS WITH EARLY-STAGE ENDOMETRIAL CARCINOMA. THE PRIMARY OBJECTIVE OF THIS STUDY IS TO IDENTIFY, IN HUMAN TUMOUR SAMPLES, BIOMARKER CHANGES ASSOCIATED TO SHORT EXPOSURE TO AZD2281 AS POTENTIAL PREDICTORS OF ACTIVITY IN ENDOMETRIAL CARCINOMA (EC). THIS IS AN EXPLORATORY STUDY WITH A BIOLOGICAL PRIMARY ENDPOINT. CLINICAL EFFICACY OR SAFETY ARE NOT A PRIMARY OBJECTIVE OF THE STUDY.